<DOC>
	<DOCNO>NCT01716806</DOCNO>
	<brief_summary>This open-label , multicenter , phase 2 clinical trial design evaluate efficacy safety brentuximab vedotin single-agent ( Part A ) combination dacarbazine ( Part B ) , bendamustine ( Part C ) , nivolumab ( Part D ) front-line therapy HL adult age 60 .</brief_summary>
	<brief_title>A Study Brentuximab Vedotin Adults Age 60 Above With Newly Diagnosed Hodgkin Lymphoma ( HL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Histopathologicallyconfirmed diagnosis classical Hodgkin lymphoma Ineligible decline initial conventional combination chemotherapy Measurable disease least 1.5 cm document radiographic technique ECOG performance status less equal 3 Symptomatic neurologic disease compromise instrumental activity daily live require medication Concurrent use investigational agent Chemotherapy , radiotherapy , biologics , and/or treatment immunotherapy complete 4 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethylauristatin E</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>